Plan A Wealth’s Myriad Genetics MYGN Stock Holding History

Plan A Wealth’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,625	Closed	-$76.8K	–	185
2025 Q3	$76.8K	Buy	+10,625	New	+$63.1K	0.04%	165

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Plan A Wealth's MYGN Position: Q4 2025 in Review

Plan A Wealth sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 10,625 shares — an estimated $76.8K sold.

Plan A Wealth first reported a position in MYGN in Q3 2025 and held it in 1 quarter. The position peaked at $76.8K in Q3 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

Plan A Wealth reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
Plan A Wealth sold 10,625 Myriad Genetics shares in Q4 2025, an estimated $76.8K.
Plan A Wealth first reported a position in Myriad Genetics in Q3 2025 and held it in 1 quarter.
Plan A Wealth's Myriad Genetics position peaked at $76.8K in Q3 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Plan A Wealth's 13F filing for Q4 2025, filed 6 Feb 2026.